Biogen expects Leqembi and new rare disease and depression treatments to help offset revenue lost from multiple sclerosis ...

often rely on over-the-counter medications called anticholinergics, such as Benadryl and Unisom. Anticholinergics induce drowsiness and block the action of acetylcholine, an important ...

Many drugs commonly prescribed to the elderly have anticholinergic properties. Due to the current clinical use of drugs with mild-to-modest anticholinergic activity, the clinical manifestations of ...

Biogen and Eisai have spent much of Leqembi’s launch convincing physicians and patients that it’s safe to treat Alzheimer’s ...

Although bronchial hyperresponsiveness to cholinergic agents is a main feature of asthma, the role of anticholinergic drugs in chronic asthma management has been largely underestimated.

Some two years into Leqembi’s launch, Eisai continues to go all-in on its Alzheimer’s disease-fighting antibody, which the ...

Trelegy Ellipta can interact with anticholinergic medications. These medications are prescribed for a variety of conditions, including overactive bladder and certain symptoms of Parkinson’s disease.

The European Commission has requested its medicines regulator to consider safety information on Eisai and Biogen's ...

The FDA last month accepted the application for subcutaneous Leqembi for maintenance dosing, with a target action date of ...

Viehbacher, “Biogen”) announced today that the U.S. Food and Drug Administration (FDA ... four weeks lecanemab-irmb (U.S. brand name: LEQEMBI ®) intravenous (IV) maintenance dosing.